Halogenated mevalonate compositions and uses thereof in ras-dependent cell growth
AssigneeBoard of Regents, The University of Texas System
InventorsJennifer A. Cuthbert, Peter E. Lipsky
Life of this patent
Estimating the term…
Abstract
Compositions that include as an active ingredient an effective concentration of a halogenated mevalonate preparation, particularly, Fmev (fluoromevalonate) are provided. The pharmacological activity of halogenated mevalonate for inhibiting ras-dependent cell growth, particularly ras-dependent tumor cell growth, is described. Methods for using preparations including a therapeutically effective concentration of Fmev for the inhibition of ras-dependent cell growth, as well as in the treatment and inhibition of ras-dependent tumors is also disclosed. The claimed compositions may be provided in liquid, salve, tablet, or capsule form, as well as other forms suitable for administration to an animal.
Claims16
A method for inhibiting proliferation of Ras-transformed cells sensitive to fluoromevalonate comprising:
- contacting cells that include Ras-transformed cells with an effective amount of fluoro mevalonate;
- and
- inhibiting proliferation of the Ras-transformed cells
- wherein cytoplasmic Ras of Ras-transformed cells is depleted and proliferation of Ras-transformed cells is selectively inhibited.
A method for inhibiting proliferation of Ras-transformed cells sensitive to treatment with fluoromevalonate in an animal comprising:
- administering a therapeutically effective amount of fluoromevalonate in a pharmaceutically acceptable carrier to said animal;
- and
- inhibiting proliferation of the Ras-transformed cells
- wherein cytoplasmic Ras of Ras-transformed cells is depleted and proliferation of Ras-transformed cells is selectively inhibited.
Dependencies are inferred from the claim text.